Takeda Pharaceutical Co. Ltd., of Osaka, Japan, and Sunovion Pharmaceuticals Inc., of Marlborough, Mass., reported data from several studies at the European College of Neuropsychopharmacology meeting in Berlin, including data showing that the use of Latuda (lurasidone), an atypical antipsychotic for adults with schizophrenia, reduced the risk of patients developing metabolic syndrome in a long-term study.